The stock has been up 19.6% compared with the industry’s gain ... Inc. REGN, ACADIA Pharmaceuticals Inc. ACAD and Aduro BioTech, Inc. ADRO. While …
Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD, both carrying a Zacks Rank ... quarters …
Accessed August 2017. [5] Patel Y et al. Pediatric multiple sclerosis. Ann Indian Acad Neurol. 2009;12(4):238-245. [6] …
Acadia Pharmaceuticals Inc. (ACAD) has been the model of inconsistency and unpredictability over the last year. ACAD is currently trading right in the middle of its 52-week range, between $16.64 and $51.99. It has risen 14% over the last …
Biotech stocks tend to be some of the most volatile names in the market, for good reason. Biotechs can be fresh, young upstarts or have a long track record. In either case, they make enormous investments in drugs that may or may not pan …
Therefore, let’s take a closer look at what smart money thinks about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). At Q3’s end, a total of 24 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -8% from …
ACAD) is struggling this afternoon, among the biotechs sitting out the broader rally. The drug stock was last seen 1.6% lower at $32.19, while its put options have caught fire. Diving right in, ACAD puts are trading at triple the usual intraday …
ACHN closed Tuesday's trading at $4.01, up 1.01%. In after-hours, the stock was up 27.68% to $5.12. ACADIA Pharmaceuticals Inc. (ACAD) reported a narrower loss for the second quarter of 2017 on higher net product sales. For …